Vissman Therapeutics

Vismann Therapeutics is a private biopharmaceutical company dedicated to the discovery and development of small molecule drugs for oncology and immune-mediated diseases. The company's core expertise lies in targeting the MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) protease, which plays a critical role in the dysregulation of the NF-κB pathway in various B-cell lymphomas. Their lead program, VT-101, is a potent and selective MALT1 inhibitor currently in late-stage preclinical development for indications including diffuse large B-cell lymphoma and mantle cell lymphoma. Beyond oncology, Vismann is exploring the potential of its MALT1 inhibitors in treating autoimmune and inflammatory conditions. The company leverages structure-based drug design and medicinal chemistry to develop highly specific therapies with improved safety profiles. Headquartered in Gaithersburg, Maryland, Vismann Therapeutics aims to address significant unmet needs in hematologic malignancies and beyond.